Wednesday, March 25, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

10% of opioid settlement funds go to lawyers

This being America, the lawsuit capital of the world, it was probably inevitable that businesses would eventually settle the crush of opioid suits as a ransom to put the issue behind them. On Wednesday state Attorneys General trumpeted a rich opioid settlement with drug distributors and Johnson & Johnson , and there will surely be more.

Thousands of lawsuits have been filed around the country that seek to hold drug manufacturers, distributors and retailers liable for the opioid epidemic. Politicians and plaintiff attorneys claim the companies hooked hundreds of thousands of Americans on opioids with deceptive marketing and negligent dispensing practices to boost their bottom line.

The main problem with this argument is that opioids such as oxycodone require a doctor’s prescription. Thousands of doctors would have to have been complicit in the conspiracy. Ditto the Drug Enforcement Administration, which is supposed to monitor and control opioid shipments by distributors to pharmacies.

Opioid prescriptions have been declining since 2012, and the vast majority of overdose deaths are now from fentanyl sold on the street, often laced with other drugs. The Centers for Disease Control and Prevention reported last week that opioid deaths increased by nearly 40% last year to 69,710 in 2020, though only 13,637 were from prescription painkillers.

But actual legal liability doesn’t count for much when the U.S. mass tort industry gets rolling. Businesses settle because they know they risk getting slammed with enormous jury verdicts if they go to trial.

Source: WSJ

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!